13F Holdings
中文EN

BGM BGM Group Ltd. Annual reports only

Pharmaceutical Preparations · Nasdaq · SEC CIK 1779578 · Fiscal year ends 09/30

Financial factors as of 2025-09-30 (FY2025), by fiscal year; growth vs the previous fiscal year

Growth

TTM revenue YoY51.1%
TTM net income YoY-1,282.1%
TTM EPS YoY10.0%
Revenue 3-yr CAGR-16.4%
Net income 3-yr CAGR—

Margins

Gross margin16.6%
Operating margin-33.2%
Net margin-52.6%
FCF margin-10.4%
EBITDA margin-29.3%

Returns

ROE-9.2%
ROA-8.2%
ROIC (approx.)-4.8%
Asset turnover0.16x

Leverage & solvency

Liabilities / assets9.7%
Debt / equity0.00x
Current ratio1.24x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.12x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue4.1%

Factor history charts and full statement history on Pro 🔒

Financial statements

Annual Quarterly (none) Export CSV 🔒
Line item FY20252025-09-30FY20242024-09-30FY20232023-09-30FY20222022-09-30FY20212021-09-30
Income statement
Revenue$37.92M$25.10M$46.47M$64.86M$57.10M
Cost of revenue$31.61M$20.98M$44.72M$58.63M$51.46M
Gross profit$6.31M$4.11M$1.75M$6.23M$5.64M
R&D expense$672,669$1.36M$568,470$1.22M$8,000
SG&A expense$18.22M$3.32M$3.79M$2.15M$2.26M
Operating income-$12.58M-$563,771-$2.61M$2.10M$2.39M
Interest expense————$57,671
Pretax income-$19.94M-$2.14M-$7.90M$1.56M$3.36M
Income tax$277,790-$619,981$219,166$194,302$255,133
Net income-$19.94M-$1.44M-$7.78M$1.08M$3.15M
EBITDA-$11.12M$673,458-$1.47M$3.33M$3.59M
EPS (basic)-0.18-0.20-1.080.150.09
EPS (diluted)-0.18-0.20-1.080.150.09
Weighted avg. shares (diluted)113.26M7.23M7.23M7.23M34.09M
Banking
Net interest income——$99,190$24,860-$57,671
Balance sheet
Cash & equivalents$9.82M$9.82M$7.48M$14.98M$12.61M
Short-term investments——$1.00M——
Receivables$4.25M$1.54M$1.98M$815,325$1.73M
Inventory$20.10M$5.05M$4.99M$8.88M$12.50M
Current assets$51.55M$29.77M$34.51M$30.03M$40.37M
PP&E, net———$10.18M$9.12M
Goodwill$350.85M————
Intangibles$4.49M$4.54M$3.42M$1.73M$1.93M
Total assets$433.81M$53.00M$51.26M$64.53M$75.35M
Current liabilities$41.60M$8.78M$6.66M$9.18M$18.17M
Total liabilities$41.92M$8.91M$6.91M$9.56M$18.68M
Shareholders' equity$390.88M$42.74M$42.79M$53.05M$54.86M
Shares outstanding200.62M7.23M7.23M7.23M35.75M
Cash flow statement
Operating cash flow-$2.37M$544,238$312,209$12.65M$345,034
Capital expenditure$1.57M$240,133$179,759$2.03M$1.49M
Free cash flow-$3.94M$304,105$132,450$10.62M-$1.15M
Investing cash flow-$162,908$983,418-$4.74M-$3.26M-$24.20M
Financing cash flow$2.62M-$491,728-$2.92M-$5.94M$23.99M
Depreciation & amortization$1.46M$1.24M$1.14M$1.22M$1.20M
Stock-based compensation$10.23M——$20,000—
Dividends paid——$1.79M——

Free plan shows the latest 5 periods; Pro shows all 8 🔒

· This company files only annual reports with the SEC (20-F for foreign issuers), so there is no quarterly data; factors are by fiscal year and growth is vs the previous fiscal year.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.